-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IvfFurCohGTavmde7NCCnVWNSuMnRmfFsEbgwN27OcrL0ION9XzrzMQSw2axGmKn ldkkDGxjyjLsWi0/A5LPWw== 0000912057-00-008344.txt : 20010524 0000912057-00-008344.hdr.sgml : 20010524 ACCESSION NUMBER: 0000912057-00-008344 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20000224 FILED AS OF DATE: 20000225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VISIBLE GENETICS INC CENTRAL INDEX KEY: 0001010819 STANDARD INDUSTRIAL CLASSIFICATION: 3826 IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: SEC FILE NUMBER: 000-28550 FILM NUMBER: 552824 BUSINESS ADDRESS: STREET 1: 700 BAY ST STREET 2: SUITE 1000 CITY: TORONTO ONTARIO CANA STATE: A6 BUSINESS PHONE: 2127025700 MAIL ADDRESS: STREET 1: 700 BAY ST STE 1000 STREET 2: TORONTO ONTARIO CANADA CITY: M5G 1Z6 6-K 1 6-K - - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FILING NO. 1 FOR THE MONTH OF FEBRUARY, 2000 VISIBLE GENETICS INC. --------------------- (Exact name of Registrant) 700 BAY STREET, SUITE 1000, TORONTO ON, CANADA M5G 1Z6 ------------------------------------------------------ (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F Form 20-F |X| Form 40-F |_| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes |_| No |X| - - -------------------------------------------------------------------------------- VISIBLE GENETICS INC. On February 24, 2000, Visible Genetics Inc. (the "Company") issued a press release to report its financial results for the fourth quarter and year ended December 31, 1999, as follows. The Company reported sales of $ 5.0 million for the fourth quarter of 1999 and $13.6 million for the year ended December 31, 1999, compared to $4.1 million and $10.9 million for the respective periods in 1998. The net loss for the fourth quarter of 1999 was $ 6.8 million or $0.76 per share, compared to a net loss of $4.4 million or $0.52 per share for the same period in 1998. For the year ended December 31, 1999, the Company reported a net loss of $25.3 million or $ 2.73 per share, compared to $14.9 million or $1.91 per share for 1998. (All amounts are in United States dollars.) The increase in the loss for the fourth quarter and the year of 1999 was due to increased expenses for clinical trials and regulatory costs related to the TruGene HIV-1 Genotyping kit, the continued growth of the Company's marketing, sales and support organizations and during the fourth quarter, $1.3 million in non-cash charges. The non-cash charges include $0.8 million related to the planned relocation of certain activities to the Company's manufacturing and marketing facilities being established in Atlanta and $0.5 million for the write off of certain patents and licenses that are no longer expected to be used by the Company. During the fourth quarter gross margins continued to improve as they increased to 40% from 35% in the third quarter of 1999. Cash and short term investments at December 31, 1999 amounted to $42.7 million, compared to $11.3 million at December 31, 1998. The Company hereby incorporates by reference this Form 6-K into the Company's outstanding Registration Statements on Form F-3 (File Nos. 333-67607, 333-68939, 333-91155 and 333-94649) and all of the Company's outstanding Registration Statements on Form S-8 (including, but not limited to, File Nos. 333-6454, 333-8804 and 333-11434). Exhibit 1. Third Quarter and 1999 Year End Results. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VISIBLE GENETICS INC. Date: February 24, 2000 By: /s/ Thomas J. Clarke ---------------------------------- Name: Thomas J. Clarke Title: Chief Financial Officer Exhibit 1 VISIBLE GENETICS INC. CONSOLIDATED BALANCE SHEETS (UNITED STATES DOLLARS)
DECEMBER 31 DECEMBER 31 1999 1998 ------------ ------------ ASSETS CURRENT ASSETS Cash and cash equivalents $ 2,792,985 $ 6,165,924 Short-term investments 39,894,978 5,108,254 Trade receivables, net of allowance for doubtful accounts 5,657,822 4,770,796 Other receivables 668,748 1,445,820 Prepaid and deposits 729,307 233,072 Inventory 2,600,007 3,912,336 ------------ ------------ TOTAL CURRENT ASSETS 52,343,847 21,636,202 FIXED ASSETS 4,173,335 3,877,163 PATENTS AND LICENSES 2,122,367 2,269,170 ------------ ------------ $ 58,639,549 $ 27,782,535 ============ ============ LIABILITIES CURRENT LIABILITIES Notes payable $ -- $ 7,494,877 Accounts payable 3,110,442 3,985,103 Accrued liabilities 3,622,110 1,723,840 ------------ ------------ TOTAL CURRENT LIABILITIES 6,732,552 13,203,820 ------------ ------------ MANDITORILY REDEEMABLE CONVERTIBLE PREFERRED STOCK 27,555,652 -- ------------ ------------ SHAREHOLDERS' EQUITY Share capital 75,422,070 46,412,685 Other equity 8,987,328 2,232,465 Cumulative translation adjustment (619,911) 84,822 Deficit (59,438,142) (34,151,257) ------------ ------------ 24,351,345 14,578,715 ------------ ------------ $ 58,639,549 $ 27,782,535 ============ ============
VISIBLE GENETICS INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNITED STATES DOLLARS)
THREE MONTHS ENDED DECEMBER 31 TWELVE MONTHS ENDED DECEMBER 31 1999 1998 1999 1998 ------------ ------------ ------------ ------------ (UNAUDITED) SALES $ 4,954,457 $ 4,078,338 $ 13,626,920 $ 10,875,348 COST OF SALES 2,954,234 2,267,852 9,272,886 6,673,581 ------------ ------------ ------------ ------------ GROSS MARGIN 2,000,223 1,810,486 4,354,034 4,201,767 EXPENSES Sales, general and administrative 6,204,167 3,860,451 19,073,546 11,515,757 Research and development 1,948,908 1,704,482 7,935,327 6,709,075 Exit and termination costs 789,849 -- 1,329,083 -- ------------ ------------ ------------ ------------ 8,942,924 5,564,933 28,337,956 18,224,832 ------------ ------------ ------------ ------------ LOSS FROM OPERATIONS BEFORE INTEREST (6,942,701) (3,754,447) (23,983,922) (14,023,065) Interest income 343,296 64,149 694,549 264,195 Interest and financing expense (214,040) (697,560) (1,997,512) (1,132,091) ------------ ------------ ------------ ------------ NET LOSS FOR THE PERIOD $ (6,813,445) $ (4,387,858) $(25,286,885) $(14,890,961) Cumulative preferred dividends and accretion of discount attributable to preferred stock (938,484) $ -- (1,770,069) $ -- ------------ ------------ ------------ ------------ NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (7,751,929) $ (4,387,858) $(27,056,954) $(14,890,961) Weighted average number of common shares outstanding 10,144,712 8,442,970 9,916,954 7,782,094 ------------ ------------ ------------ ------------ BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.76) $ (0.52) $ (2.73) $ (1.91) ============ ============ ============ ============
VISIBLE GENETICS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (UNITED STATES DOLLARS)
TWELVE MONTHS ENDED DECEMBER 31 1999 1998 ------------ ------------ CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES Net Loss for the year $(25,286,885) $(14,890,961) Add: Items not involving cash - Depreciation 1,708,923 1,090,086 Amortization 393,979 206,640 Patents and licenses written off 451,085 -- Deferred compensation cost related to options granted -- 77,469 Non cash financing expense related to warrants granted 1,466,691 580,981 Amortization of discount on accounts receivable (48,158) -- Foreign exchange loss 26,789 28,453 In-process research and development acquired -- 420,043 Increase ( decrease ) from changes in - Trade receivables (1,804,006) (2,327,121) Other receivables 719,519 (850,270) Prepaid and deposits (501,742) 28,913 Inventory 1,290,997 (3,149,740) Accounts payable (734,230) 2,490,594 Accrued liabilities 1,956,660 1,159,952 ------------ ------------ (20,360,378) (15,134,961) ============ ============ INVESTING ACTIVITIES Purchase of fixed assets (1,905,129) (3,348,261) Licenses and patents acquired (698,261) (877,796) Purchase of short-term investments (50,503,643) (13,705,737) Redemption of short-term investments 15,716,919 14,616,777 Acquisition of ACT Gene S.A -- (536,929) ------------ ------------ (37,390,114) (3,851,946) ============ ============ FINANCING ACTIVITIES Preferred stock issued, net of expenses 22,719,748 -- Warrants issued in connection with preferred stock 6,397,448 -- Common shares issued, net of expenses 29,009,385 14,640,188 Warrants issued in connection with private placement -- 444,572 Issuance of notes payable -- 6,817,559 Warrants issued in connection with notes payable -- 1,182,441 Repayment of note payable (4,100,000) -- Other equity 29,851 8,259 Repayment of loan from an officer 323,405 -- ------------ ------------ 54,379,837 23,093,019 ============ ============ EFFECT OF EXCHANGE RATE FLUCTUATIONS ON CASH (2,284) 193,133 ------------ ------------ INCREASE (DECREASE) IN CASH DURING THE YEAR (3,372,939) 4,299,245 CASH, BEGINNING OF YEAR 6,165,924 1,866,679 ------------ ------------ CASH, END OF YEAR $ 2,792,985 $ 6,165,924 ============ ============
VISIBLE GENETICS INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNITED STATES DOLLARS)
TWELVE MONTHS ENDED DECEMBER 31 1999 1998 ------------ ------------ Net loss for the year $(25,286,885) $(14,890,961) Other comprehensive income: Foreign currency translation adjustments (704,733) 112,477 ------------ ------------ Comprehensive loss for the year $(25,991,618) $(14,778,484) ------------ ------------
VISIBLE GENETICS INC. CONSOLIDATED STATEMENTS OF DEFICIT (UNITED STATES DOLLARS)
TWELVE MONTHS ENDED DECEMBER 31 1999 1998 ------------ ------------ Deficit, beginning of year $(34,151,257) $(19,260,296) Net loss for the year (25,286,885) (14,890,961) ------------ ------------ Deficit, end of the year $(59,438,142) $(34,151,257) ------------ ------------
-----END PRIVACY-ENHANCED MESSAGE-----